1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,200 | 7,200 | 19:56 |
► 14.08.: | | | | | | | | |
► 13.08.: | | | | | | | | |
► Aktueller 4BASEBIO Börsenkurs + Xetra-Orderbuch
► 13.08.: | | | | | | | | |
► Aktueller 4BASEBIO Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 22,200 | 30 | |||
| 15,000 | 15 | |||
| 11,000 | 500 | |||
| 7,200 | 1.564 | |||
| 6,350 | 500 | |||
| 6,050 | 715 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 715 | 5,700 | |||
| 1.564 | 5,200 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 4.040 | 0,832 | 3.363 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | 0,000 0,00 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.07. | 4basebio Plc - Grant of Options & Director/PDMR Dealing | 370 | PR Newswire | 4basebio Plc - Grant of Options & Director/PDMR Dealing
PR Newswire
LONDON, United Kingdom, July 22
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 08.07. | 4basebio Plc - Director Appointment | 584 | PR Newswire | 4basebio Plc - Director Appointment
PR Newswire
LONDON, United Kingdom, July 08
4basebio PLC
("4basebio" or the "Company")
... ► Artikel lesen | |
| 30.06. | 4basebio Plc - Result of AGM & Issue of Options | 422 | PR Newswire | 4basebio Plc - Result of AGM & Issue of Options
PR Newswire
LONDON, United Kingdom, June 30
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 16.06. | 4basebio Plc - Notice of Investor Presentation | 410 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| 15.06. | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News |
1 2 3 4 5 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:03 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 13:18 | Outlook Therapeutics, Inc.: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA | GlobeNewswire (Europe) | The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA... ► Artikel lesen | |
| 14:48 | Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | GlobeNewswire (Europe) | Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center... ► Artikel lesen | |
| 14:36 | BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site | GlobeNewswire (Europe) | NETANYA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a company focused on defense, security and critical infrastructure technologies, today... ► Artikel lesen | |
| 14:06 | Replimune Group, Inc.: Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update | GlobeNewswire (Europe) | TUDRIQEV in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 4BASEBIO PLC finden Sie auf Wallstreet Online.